LatusPet offers SINO, a metabolomics blood test for cats and dogs that screens for cancer and systemic diseases before symptoms appear. Using a single blood sample, the test analyzes hundreds of biomarkers across metabolomics, lipidomics, and proprietary omics layers, with AI-powered pattern recognition delivering Low, Moderate, or High risk reports to veterinarians. The test is available through veterinary practices and is recommended annually as part of routine wellness care.
Funding
Funding not disclosed
Founders
Product
Problem
Dogs and cats instinctively hide signs of illness, so by the time symptoms become visible, many diseases have already progressed significantly. Standard veterinary blood panels check only a handful of markers and often fail to detect early-stage cancer or systemic disease, limiting treatment options and outcomes.
Solution
SINO is a metabolomics blood test that screens for cancer and systemic diseases in cats and dogs before clinical symptoms appear. From a single blood sample of less than 1ml, the test quantifies hundreds of biomarkers across three complementary data layers—metabolomics, lipidomics, and proprietary omics data—to capture a comprehensive picture of cellular health. A proprietary AI engine trained on thousands of metabolomics profiles identifies complex disease signatures that conventional panels cannot detect, and delivers results as a clear, structured risk report with Low, Moderate, or High categories and actionable guidance. The system continuously learns from every validated sample, building a proprietary veterinary metabolomics AI dataset that improves accuracy and disease specificity over time.
Target Audience
Primary customers are veterinary practices that integrate SINO into routine wellness care, along with cat and dog owners who seek early disease detection for their pets through their veterinarians.
Features
- Single blood sample (<1ml) with no fasting, sedation, or special preparation required
- Integrates three biological data layers: metabolomics, lipidomics, and proprietary omics data
- AI-powered pattern recognition engine trained on thousands of metabolomics profiles to detect disease-associated signatures
- Detects early-stage cancer, organ dysfunction, and systemic disease across multiple panels including cardiovascular and atopic dermatitis markers
- Results delivered as unambiguous Low, Moderate, or High risk categories with panel breakdowns and recommended next steps
- Pre-labelled collection kits with prepaid postage and tracked sample logistics for seamless integration into any veterinary practice
- Continuous learning loop where every validated sample improves the AI model's precision and scope